<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'>
<collection>
  <source>SourceData</source>
  <date>00000000</date>
  <key>sourcedata.key</key>
  <document>
    <id>4492819 Figure_1-A</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 1-A</infon>
    <infon key="sourcedata_figure_dir">Figure_1-A</infon>
    <passage>
      <offset>0</offset>
      <text>A, B BMDCs were treated with OxPAPC or DPPC (40 &#956;g/ml) for 60 min followed by R837 stimulation (5 &#956;g/ml). (A) Supernatants were harvested after 18 h, and concentrations of IL-6 and IL-12 were quantified by ELISA. One-way ANOVA adjusted by Dunnett's multiple comparisons test. Mean &#177; SD of triplicate determinations from &gt; 3 independent experiments are shown.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_1-B</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 1-B</infon>
    <infon key="sourcedata_figure_dir">Figure_1-B</infon>
    <passage>
      <offset>0</offset>
      <text>A, B BMDCs were treated with OxPAPC or DPPC (40 &#956;g/ml) for 60 min followed by R837 stimulation (5 &#956;g/ml). (B) mRNA was harvested after 2 h, and expression of IL-6 and IL-12 was measured by real-time PCR and normalized to G6pdx. Unpaired two-tailed t-test. Data (mean &#177; SD) are representative of three independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_1-C</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 1-C</infon>
    <infon key="sourcedata_figure_dir">Figure_1-C</infon>
    <passage>
      <offset>0</offset>
      <text>C Bioactive OxPAPC mixtures were obtained by various oxidation protocols from highly pure PAPC. Periods of oxidation were 24 h for CuSO4 (10 &#956;M), 48 h for FeSO4 (10 &#956;M), and 72 h for air. BMDCs were treated for 60 min with lipids prior stimulation with R837 (5 &#956;g/ml) for 18 h. Cytokine concentrations in supernatants were quantified by ELISA. One-way ANOVA adjusted by Dunnett's multiple comparisons test. Data represent mean &#177; SEM of triplicate determinations.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_1-D</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 1-D</infon>
    <infon key="sourcedata_figure_dir">Figure_1-D</infon>
    <passage>
      <offset>0</offset>
      <text>D PAPC (40 &#956;g/ml) oxidized with CuSO4 (10 &#956;M) for the indicated times was used for treatment of BMDCs prior to R837 (5 &#956;g/ml) stimulation and measurement of IL-12 secretion. Mean &#177; SEM of triplicate determinations from three different oxidation series are shown.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_1-E-F</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 1-E-F</infon>
    <infon key="sourcedata_figure_dir">Figure_1-E-F</infon>
    <passage>
      <offset>0</offset>
      <text>E, F Treatment of BMDCs with the indicated concentrations of CuSO4-oxidized PAPC suppressed IL-6 (E) and IL-12 (F) secretion triggered by a variety of different TLR agonists. After OxPAPC treatment for 60 min, BMDCs were stimulated for 18 h with LTA (500 ng/ml), Poly I:C (50 &#956;g/ml), LPS (10 ng/ml), R837 (5 &#956;g/ml), and CpG (100 nM). Cytokine concentrations in the supernatant were quantified by ELISA. Data are shown as mean &#177; SD of triplicate determinations from three independent experiments and were analyzed by one-way ANOVA adjusted by Dunnett's multiple comparisons test.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_1-G-H-I</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 1-G-H-I</infon>
    <infon key="sourcedata_figure_dir">Figure_1-G-H-I</infon>
    <passage>
      <offset>0</offset>
      <text>G-I Splenicdendritic cells were treated with OxPAPC or DPPC (40 &#956;g/ml) before co-culturing with na&#239;ve transgenic SMARTA CD4T cells in the presence of the specific peptide gp61. (G) After 4 days of cell culture, T-cell polarization was assessed by intracellular staining for the cytokines IL-4 (Th2) and IFN-&#947; (Th1). (H) Bar graphs represent the frequencies of IL-4- and IFN-&#947;-producing T cells after 4 days of co-culture with OxPAPC-treated and DPPC-treated splenicdendritic cells. Bars represent mean &#177; SD of duplicate experiments. *P &#8804; 0.05 by unpaired two-tailed t-test. (I) IFN-&#947; production in supernatants of SMARTA CD4T cells (stimulated with 1,000 nM gp61) and co-cultured with OxPAPC- and DPPC-treated splenicdendritic cells for 4 days. One-way ANOVA adjusted by Dunnett's multiple comparisons test. Bars represent mean &#177; SD.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_2-A</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 2-A</infon>
    <infon key="sourcedata_figure_dir">Figure_2-A</infon>
    <passage>
      <offset>0</offset>
      <text>Mass spectrometric quantification of a variety of OxPL species obtained by CuSO4-catalyzed oxidation of PAPC for 2 and 24 h. Mean &#177; SEM of duplicate determinations are shown.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_2-B</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 2-B</infon>
    <infon key="sourcedata_figure_dir">Figure_2-B</infon>
    <passage>
      <offset>0</offset>
      <text>Correlation between the abundance of individual OxPL species detected in mixtures of differentially oxidized OxPL preparations and the capacity of the respective overall OxPL mixtures to suppress the IL-12 secretion of thioglycollate-elicited macrophages. Dots represent data of individual OxPAPC preparations.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_3-A</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 3-A</infon>
    <infon key="sourcedata_figure_dir">Figure_3-A</infon>
    <passage>
      <offset>0</offset>
      <text>Selected candidate lipids were tested for their inhibitory activity on R837-induced (5 &#956;g/ml; 18 h) cytokine secretion in BMDCs. Concentrations of indicated lipids: PECPC (10 &#956;M), PEIPC (10 &#956;M), OxPAPC (40 &#956;g/ml), DPPC (40 &#956;g/ml), POVPC (40 &#956;M), PGPC (40 &#956;M), and KOdiAPC (40 &#956;M). Representative data (mean &#177; SD of triplicate determinations) from one of three independent experiments are shown. ****P &lt; 0.0001; ns, not significant; as determined by one-way ANOVA adjusted by Sidak's multiple comparisons test.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_3-C</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 3-C</infon>
    <infon key="sourcedata_figure_dir">Figure_3-C</infon>
    <passage>
      <offset>0</offset>
      <text>Dose-response curves of IL-12 secretion in BMDCs pulsed for 60 min with the indicated lipids, followed by stimulation with R837 (5 &#956;g/ml) for 18 h. Toxic concentrations of lipids were excluded from analysis. Mean &#177; SEM of triplicate determinations are shown.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_3-D</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 3-D</infon>
    <infon key="sourcedata_figure_dir">Figure_3-D</infon>
    <passage>
      <offset>0</offset>
      <text>EC50 values of anti-inflammatory lipid products normalized to the capacity of 15d-PGJ2 to suppress IL-12 production in BMDCs (left panel) and their respective bioactivities (right panel) depicted as the fold increase relative to 15d-PGJ2. Mean &#177; SEM of triplicate determinations are shown.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_3-E</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 3-E</infon>
    <infon key="sourcedata_figure_dir">Figure_3-E</infon>
    <passage>
      <offset>0</offset>
      <text>IL-12 production of BMDC stimulated via TLR 4 (LPS; 100 ng/ml), TLR 9 (CpG; 100 nM), and TLR 7 (R837; 5 &#956;g/ml) after pretreatment with the indicated free and esterified versions of EC and 15d-PGJ2. Lipids were used at 1 &#956;M (EC), 10 &#956;M (PECPC), or 20 &#956;M (15d-PGJ2 and 15d-PGJ2PC). Data (mean &#177; SEM) are representative of 3 independent experiments. **P &#8804; 0.01; ***P &#8804; 0.001; ****P &#8804; 0.0001; determined by one-way ANOVA adjusted by Dunnett's multiple comparisons test.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_3-F</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 3-F</infon>
    <infon key="sourcedata_figure_dir">Figure_3-F</infon>
    <passage>
      <offset>0</offset>
      <text>Analysis of the capacity of various OxPL-derived species to license splenicdendritic cells to polarize na&#239;ve CD4T cells toward the Th2 subset. Concentrations of indicated lipids: EC (1 &#956;M), PECPC (10 &#956;M), 15d-PGJ2 (20 &#956;M), OxPAPC (40 &#956;g/ml), DPPC (40 &#956;g/ml), POVPC (40 &#956;M), PGPC (40 &#956;M), KOdiAPC (40 &#956;M).</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_4-A</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 4-A</infon>
    <infon key="sourcedata_figure_dir">Figure_4-A</infon>
    <passage>
      <offset>0</offset>
      <text>A IL-12 production of BMDC from wild-type, Nrf2&#8722;/&#8722;, Pparg&#8722;/&#8722;, and Pparg litter mate control mice normalized to medium control (open bars). Cells were treated with the indicated lipids (filled bars) for 60 min prior TLR 7 ligation with R837 (5 &#956;g/ml) for 18 h. Lipids were used at starting concentrations of 40 &#956;M (POVPC, PGPC, and KOdiAPC), 40 &#956;g/ml (OxPAPC), 20 &#956;M (15d-PGJ2), and 1.25 &#956;M (EC), depicted as black bars, and 2-fold serial dilutions thereof (gray bars). Data represent mean &#177; SEM of triplicates from one of three independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_4-B</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 4-B</infon>
    <infon key="sourcedata_figure_dir">Figure_4-B</infon>
    <passage>
      <offset>0</offset>
      <text>B Expression of Nrf2 target genes Hmox1 and Nqo1 in wild-type and Nrf2&#8722;/&#8722;BMDM stimulated with EC (2 &#956;M) for 60 min. Gene expression levels are presented relative to that of untreated cells after normalization to G6pdx. Data (mean &#177; SEM) are representative of two independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_4-C-D</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 4-C-D</infon>
    <infon key="sourcedata_figure_dir">Figure_4-C-D</infon>
    <passage>
      <offset>0</offset>
      <text>C, D mRNA expression levels of the Nrf2 targets Gclc and Gsta3 (C) and of the pro-inflammatory cytokines IL-6 and IL-12 (D) in wild-type, PPAR-&#947;-deficient, and Nrf2-deficient BMDM after treatment with EC or 15d-PGJ2 for 60 min followed by LPS treatment for 3 h. Expression levels are normalized to G6pdx. Data represent mean &#177; SEM of triplicate cultures from one of two independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_4-E</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 4-E</infon>
    <infon key="sourcedata_figure_dir">Figure_4-E</infon>
    <passage>
      <offset>0</offset>
      <text>E mRNA expression of the indicated chemokines as determined by qPCR. Wild-type BMDCs were treated with EC (1 &#956;M) or 15d-PGJ2 (20 &#956;M) for 60 min followed by R837 stimulation (5 &#956;g/ml) for 3 h. Expression levels are shown normalized to G6pdx. Data (mean &#177; SEM, n = 2) are representative of three independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_5-A-B-C</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 5-A-B-C</infon>
    <infon key="sourcedata_figure_dir">Figure_5-A-B-C</infon>
    <passage>
      <offset>0</offset>
      <text>A C57BL/6mice were treated (i.v.) with 500 &#956;g EC or DPPC control 2 h prior to i.p injection of 150 ng/g LPS together with 800 &#956;g/g D-galactosamine. 4 h after LPS application, lungs were perfused with PBS and embedded in paraffin. Tissue sections were hematoxylin-stained to visualize adherent cells. Bars represent 100 &#181;m. B, C Leukocyte adhesion to lung microvascular endothelium as determined by morphometric image analysis of lung tissue sections is presented for individual vessels in (B) and as averages of single mice in (C). Pooled data of two independent experiments are shown (n = 10 for EC, n = 14 for DPPC). Unpaired two-tailed t-test.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_5-D-E</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 5-D-E</infon>
    <infon key="sourcedata_figure_dir">Figure_5-D-E</infon>
    <passage>
      <offset>0</offset>
      <text>D, E C57BL/6mice were treated with EC or DPPC by intra-tracheal instillation at 18 h (50 &#956;g) and 1.5 h (100 &#956;g) prior to i.p. injection of 150 ng/g LPS and 800 &#956;g/g D-galactosamine. Bar graphs represent absolute numbers of total infiltrating cells and of neutrophils (D). Unpaired two-tailed t-test. Data represent mean &#177; SEM from one of two independent experiments with at least 6 mice per group. (E) Dot plots depict exemplary gating of lungneutrophils on pregated CD45+CD11c&#8722;SiglecF&#8722; BAL cells of EC-/LPS-treated and DPPC-/LPS-treated mice.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_5-F-G</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 5-F-G</infon>
    <infon key="sourcedata_figure_dir">Figure_5-F-G</infon>
    <passage>
      <offset>0</offset>
      <text>F, G The concentrations of IL-6 (F) and IL-12 (G) in the BAL of mice treated as in (D) were quantified by ELISA. Data (mean &#177; SEM) are representative of two independent experiments with 3 mice per group. ****P &lt; 0.0001; unpaired two-tailed t-test.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_5-H</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 5-H</infon>
    <infon key="sourcedata_figure_dir">Figure_5-H</infon>
    <passage>
      <offset>0</offset>
      <text>C57BL/6mice were treated with EC or DPPC by intra-tracheal instillation at 18 h (50 &#956;g) and 1.5 h (100 &#956;g) prior to i.p. injection of 150 ng/g LPS and 800 &#956;g/g D-galactosamine. (E) Dot plots depict exemplary gating of lungneutrophils on pregated CD45+CD11c&#8722;SiglecF&#8722; BAL cells of EC-/LPS-treated and DPPC-/LPS-treated mice.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_6-A-B</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 6-A-B</infon>
    <infon key="sourcedata_figure_dir">Figure_6-A-B</infon>
    <passage>
      <offset>0</offset>
      <text>Dose-response curves showing the modulation of R837-induced (5 &#956;g/ml; 18 h) IL-12 secretion by prior treatment of BMDCs with the indicated synthetic lipids for 1 h. Chemical structures and &#916;EC50 values of the synthetic OxPL variant lipids analyzed in (A), presented relative to EC.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_7-B</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 7-B</infon>
    <infon key="sourcedata_figure_dir">Figure_7-B</infon>
    <passage>
      <offset>0</offset>
      <text>Quantification of IL-6 and IL-12 secretion by BMDC treated with 250 nM cEC or EC for 60 min before stimulation with R837 (5 &#956;g/ml; 18 h). Bars represent mean &#177; SEM from one of three independent experiments. **P &lt; 0.01; ***P &lt; 0.001; one-way ANOVA adjusted by Dunnett's multiple comparisons test.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_7-C</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 7-C</infon>
    <infon key="sourcedata_figure_dir">Figure_7-C</infon>
    <passage>
      <offset>0</offset>
      <text>mRNA expression of the Nrf2 targets Hmox1 and Nqo1 normalized to G6pdx expression. BMDCs were treated for 60 min with 500 nM cEC or DPPC followed by R837 stimulation (5 &#956;g/ml) for 3 h. Data (mean &#177; SD) are representative of three independent experiments. *P &lt; 0.05; **P &lt; 0.01; unpaired two-tailed t-test.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_7-D-E</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 7-D-E</infon>
    <infon key="sourcedata_figure_dir">Figure_7-D-E</infon>
    <passage>
      <offset>0</offset>
      <text>&#916;EC50 values of the indicated lipids and OxPL shown relative to that of EC as determined in (E). Dose-response curves showing the modulation of R837-induced (5 &#956;g/ml; 18 h) IL-12 secretion in BMDCs by prior treatment with the indicated OxPL derivatives for 1 h.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_7-F</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 7-F</infon>
    <infon key="sourcedata_figure_dir">Figure_7-F</infon>
    <passage>
      <offset>0</offset>
      <text>mRNA quantification of the indicated chemokines relative to G6pdx expression. BMDC were pretreated for 60 min with 500 nM cEC or the variant BisRed prior to R837 stimulation (5 &#956;g/ml) for 3 h. Data (mean &#177; SD) are representative of three independent experiments. *P &lt; 0.05; **P &lt; 0.01; unpaired two-tailed t-test.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_7-G</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 7-G</infon>
    <infon key="sourcedata_figure_dir">Figure_7-G</infon>
    <passage>
      <offset>0</offset>
      <text>Quantification and characterization of cellular infiltrates in BAL. Groups of six C57BL/6mice were pretreated i.t. with 50 &#956;g cEC, EC, or BisRed 24 and 2 h before challenge with 150 ng/g LPS in the presence of 800 &#956;g/g D-galactosamine. BAL was harvested 4 h after LPS injection, and inflammatory cells were characterized by FACS analysis. **P &lt; 0.01; ****P &lt; 0.0001; one-way ANOVA with Sidak's multiple comparisons test.</text>
    </passage>
  </document>
  <document>
    <id>4492819 Figure_7-H</id>
    <infon key="sourcedata_document">1422</infon>
    <infon key="doi">10.15252/emmm.201404702</infon>
    <infon key="pmc_id">4492819</infon>
    <infon key="figure">Figure 7-H</infon>
    <infon key="sourcedata_figure_dir">Figure_7-H</infon>
    <passage>
      <offset>0</offset>
      <text>Comparison of the capacity of cEC, EC, and PECPC (1 &#956;M) to license splenicdendritic cells to polarize na&#239;ve CD4T cells into IFN-&#947;-producing (Th1) and IL-4-producing (Th2) effector cells. Data (mean &#177; SD) are representative of two independent experiments. One-way ANOVA adjusted by Dunnett's multiple comparisons test. *P &lt; 0.05; **P &lt; 0.01; ***P &lt; 0.001; ****P &lt; 0.0001.</text>
    </passage>
  </document>
</collection>
